Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00325065 · ClinicalTrials.gov registry record
Identifying the Role of Oxytocin and Vasopressin in the Functioning of Neurocognitive Systems Involved in Mood Disorders
A clinical trial of Mood Disorders, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- 71
- Enrollment target
- 1
- Study location
NCT00325065: Completed study of Mood Disorders, sponsored by National Institute of Mental Health (NIMH).
NCT00325065 is a study of Mood Disorders that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 71 participants, below the 936-participant average among 39 other Mood Disorders trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00325065, a study of Mood Disorders, has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- 71 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this protocol, broadly stated, is to use targeted manipulations with intranasally administered oxytocin (OT) and arginine vasopressin (AVP) in conjunction with neurocognitive and neuroimaging paradigms to evaluate claims that OT and AVP inhibit and facilitate, respectively, the effective processing of aversive signals. Moreover, we wish to examine whether increased vasopressin levels will increase, and increased oxytocin levels decrease, the neural response in the amygdala and other limbic structures to aversive stimuli. In addition, we wish to assess whether OT and AVP administration will lead to the facilitation of conspecific recognition as appears to be the case for other mammalian species....
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2006-05-05 |
| Est. Completion | 2010-04-16 |
What the finished NCT00325065 record still lists
NCT00325065 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 936-participant average among 39 other Mood Disorders trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Mood Disorders appearing as the primary indexed condition, and to 0 interventions.
NCT00325065 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00325065 about?
NCT00325065 is a clinical study titled "Identifying the Role of Oxytocin and Vasopressin in the Functioning of Neurocognitive Systems Involved in Mood Disorders". The goal of this protocol, broadly stated, is to use targeted manipulations with intranasally administered oxytocin (OT) and arginine vasopressin (AVP) in conjunction with neurocognitive and neuroimaging paradigms to evaluate claims that OT and AVP inhibit and facilitate, respectively, the effective...
What is the current status of trial NCT00325065?
This trial is currently completed. The enrollment target is 71 participants. The study started on 2006-05-05. Estimated completion is 2010-04-16.
What conditions does trial NCT00325065 study?
This clinical trial studies the following conditions: Mood Disorders.
Who is sponsoring clinical trial NCT00325065?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00325065 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mood Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00325065's enrollment target sits among peer trials
71 31st of 39 higher than 9 of 39 other Mood Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mood Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cold and Heat Investigation to Lower Levels of Depression
RECRUITING · NA
-
Suicide Specific Rumination in Veterans
RECRUITING · NA
-
Clinical Validation of Samsung Smartwatch
RECRUITING
-
A Preventive Behavioral Intervention for Young Adults With Psychotic Experiences
RECRUITING · NA
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
Resilience in Adolescent Development
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI